Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty

被引：114

作者：

Romanò, CL

Duci, D

Romanò, D

Mazza, M

Meani, E

机构：

[1] Ist Ortoped Gaetano Pini, Dept Orthopaed Surg COS, I-20121 Milan, Italy

[2] Ist Ortoped Gaetano Pini, Dept Orthopaed Surg, Div 1, I-20121 Milan, Italy

来源：

JOURNAL OF ARTHROPLASTY | 2004年 / 19卷 / 01期

关键词：

celecoxib; indomethacin; COX-2; heterotopic ossification; hip prosthesis; total hip replacement;

D O I：

10.1016/S0883-5403(03)00279-1

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

A cyclo-oxygenase (COX)-1 and COX-2 inhibitor (indomethacin) and a selective COX-2 inhibitor (celecoxib) were compared in the prevention of heterotopic ossification after total hip arthroplasty. In 250 patients receiving indomethacin and in 150 patients receiving celecoxib for 20 days after surgery, an overall incidence of heterotopic ossification of 17.5% and 14.3% was seen, respectively (difference not statistically significant: P >.05). No grade III or IV ossifications were seen in either group. Twenty-one patients in the indomethacin group (8.4%) and 3 patients in the celecoxib group (2.0%) required treatment discontinuation, because of side effects (P <.05). Celecoxib, a selective COX-2 inhibitor, shows the same efficacy as indomethacin in the prevention of heterotopic ossification after hip prosthesis with significantly fewer side effects.

引用

页码：14 / 18

页数：5

共 32 条

[1]

EXTRA-OSSEOUS LOCALIZED NON-NEOPLASTIC BONE AND CARTILAGE FORMATION (SO-CALLED MYOSITIS OSSIFICANS) - CLINICAL AND PATHOLOGICAL CONFUSION WITH MALIGNANT NEOPLASMS [J].